March 6: Avio Smart Market Stack Limited (ASMS), formerly known as Bartronics India Limited, has initiated an expanded collaboration with Huwel Lifesciences to introduce a range of patented molecular diagnostic products across multiple healthcare segments in India.
The development follows the recently signed Shareholders’ Agreement between the two companies, under which they aim to jointly scale advanced diagnostic technologies and bring them to institutional and healthcare markets across the country.
Huwel Lifesciences has developed multiple patented diagnostic technologies and is building a strong pipeline of new products, with several additional patents and platforms currently under development. The company’s capabilities span RT-PCR diagnostic kits, point-of-care molecular testing devices, and disease detection panels. Research, assay development, and manufacturing are carried out within Huwel’s own facilities.
Positioning itself as a fully indigenous diagnostics innovator, Huwel is among the few molecular diagnostics companies in India with the capability to design, develop, and manufacture most components of its diagnostic platforms in-house, aligning with the Government of India’s “Make in India” initiative.
India represents one of the largest markets globally for infectious disease diagnostics. National health programs and institutional healthcare networks together conduct tens of millions of diagnostic tests annually for diseases such as tuberculosis, HIV, hepatitis, and other infectious conditions. The diagnostics market for these diseases alone is estimated to exceed ₹5,000 crore annually in India.
Huwel’s molecular diagnostic solutions are designed to enable rapid and cost-efficient tuberculosis detection using open RT-PCR systems, allowing tests to run on RT-PCR laboratory infrastructure that was widely deployed across the country during the COVID-19 pandemic. This approach enables scalable public health testing without requiring significant new infrastructure investments.
The company’s tuberculosis molecular diagnostic platform has already received the necessary regulatory approvals and validations. Building on the same technology platform, Huwel has also developed molecular diagnostics for HIV, HPV-based cervical cancer screening, antimicrobial resistance (AMR) surveillance, hepatitis, and several other infectious diseases, using scalable open RT-PCR systems suitable for large-scale testing.
As part of the collaboration, Avio Smart Market Stack will support the go-to-market strategy, institutional engagement, and commercialization of these technologies by leveraging its institutional relationships, digital infrastructure capabilities, and experience in executing large-scale programs.
Commenting on the collaboration, Mr. Vidhyasagar Reddy, Managing Director, Avio Smart Market Stack Limited, said:
“India has a significant opportunity to strengthen its public health infrastructure through indigenous diagnostic innovation. Our collaboration with Huwel Lifesciences brings together advanced molecular diagnostic technologies and our institutional market access capabilities. By leveraging the extensive RT-PCR infrastructure established across the country during the pandemic, we aim to accelerate the availability of rapid, accurate, and affordable diagnostics for diseases such as tuberculosis, HIV, hepatitis, and other infectious conditions. This partnership aligns with our broader vision of supporting scalable health-tech solutions that can improve healthcare access across India.”
Over the coming years, ASMS and Huwel expect to introduce multiple diagnostic product lines across different disease segments, expanding the availability of indigenous molecular diagnostics across government health programs, hospital networks, diagnostic laboratories, and private healthcare providers.